Inhibition of PKM2 Enhances Sensitivity of Olaparib to Ovarian Cancer Cells and Induces DNA Damage

Related Experiment Video

Updated: Sep 30, 2025

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

38.2K

Sichun Zhou1, Duo Li1, Di Xiao1

  • 1Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, 410013, China; Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Yantai University, Yantai, 264005, China.

International Journal of Biological Sciences
|March 14, 2022
PubMed

Insights

Downregulating pyruvate kinase M2 (PKM2) enhances the effectiveness of poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer. This strategy improves anti-tumor activity and DNA damage response, offering a new therapeutic approach.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Poly (ADP-ribose) polymerase inhibitors (PARPi) are effective maintenance therapy for advanced ovarian cancer by targeting homologous recombination (HR).
  • Pyruvate kinase M2 (PKM2) is a key metabolic enzyme that promotes HR and DNA repair in cancer cells.

Purpose of the Study:

  • To investigate the role of PKM2 downregulation in sensitizing ovarian cancer cells to PARPi.
  • To elucidate the molecular mechanisms underlying PKM2 inhibition in enhancing PARPi efficacy.

Main Methods:

  • In vitro assays including cell viability, clone formation, transwell migration, and flow cytometry.
  • Western blot and immunofluorescence to assess DNA damage markers (γH2AX, p-ATM) and BRCA1 nuclear accumulation.
  • In vivo xenograft animal model and analysis of tissue samples.

Main Results:

  • PKM2 downregulation (siRNA or shikonin) synergized with olaparib (Ola), enhancing anti-tumor activity and inducing apoptosis.
  • PKM2 inhibition amplified Ola-induced DNA damage signaling and disrupted BRCA1 nuclear localization.
  • Combination therapy demonstrated in vivo efficacy and increased DNA damage in tumor tissues.

Conclusions:

  • PKM2 downregulation is a novel strategy to enhance olaparib effectiveness in ovarian cancer.
  • Targeting PKM2 can overcome resistance mechanisms and improve PARPi therapy outcomes.
Keywords:
DNA damagePKM2homologous recombinationolaparibovarian cancer

More Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.8K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.1K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.3K
DNA Damage Can Stall the Cell Cycle02:37

DNA Damage Can Stall the Cell Cycle

2.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K